Sakiko Yamada

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Bipolar Disorder

Top Venues

Neuropsychopharmacology reports

Neuropsychiatric disease and treatment

Human psychopharmacology

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Akitoyo Hishimoto, Yasui-Furukori Norio, Daisuke Sekine, Miyuki Matsukawa, Sakiko Yamada
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study. Advances in therapy 39 (9) (2022)
Jun Ishigooka, Ken Inada, Kazunari Niidome, Kazuo Aoki, Yoshitsugu Kojima, Shuichi Iwashita, Sakiko Yamada
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. Human psychopharmacology 36 (4) (2021)
Takeshi Inoue, Hiromi Sano, Yoshitsugu Kojima, Sakiko Yamada, Osamu Shirakawa
Real-World Treatment Patterns and Adherence to Oral Medication Among Patients with Bipolar Disorders: A Retrospective, Observational Study Using a Healthcare Claims Database. Neuropsychiatric disease and treatment 17 (2021)
Ken Inada, Sakiko Yamada, Hisashi Akiyoshi, Yoshitsugu Kojima, Shuichi Iwashita, Jun Ishigooka
Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study. Neuropsychiatric disease and treatment 16 (2020)
Yoshinori Watanabe, Sakiko Yamada, Tempei Otsubo, Toshiaki Kikuchi
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective. Drug design, development and therapy 14 (2020)